What question did this study set out to answer?

To investigate the role of PHD inhibitors like Roxadustat in increasing TPI protein levels in FB909 cells.

May 15, 2026Journal of Cell Science0 citations

First person – Presley Roberts

Key Points

To investigate the role of PHD inhibitors like Roxadustat in increasing TPI protein levels in FB909 cells.
Interview with Presley Roberts, first author of the study on PHD inhibitors.
Biophysical and biochemical analyses, including western blotting, were used to assess TPI protein levels.
Research conducted in Dr. Michael Palladino's lab at the University of Pittsburgh.
PHD inhibitors significantly increased TPI protein levels in FB909 cells.
Western blotting confirmed the effectiveness of Roxadustat as a promising therapy for TPI deficiency.

Abstract

First Person is a series of interviews with the first authors of a selection of papers published in Journal of Cell Science, helping researchers promote themselves alongside their papers. Presley Roberts is first author on ‘ Biophysical and biochemical studies support PHD inhibitor development as a TPI deficiency therapy’, published in JCS. Presley is a Research Technician IV in the lab of Dr Michael Palladino at University of Pittsburgh School of Medicine, USA, investigating how prolyl hydroxylase domain inhibitors (PHDIs) like Roxadustat significantly increase triosephosphate isomerase (TPI) protein levels in FB909 cells (derived from individuals with triosephosphate isomerase deficiency), as demonstrated by western blotting.

Ask AI

Helpful

Bookmark

View Full Paper